FiercePharmaAsia—CFDA, Celltrion, WuXi NextCODE by Angus Liu Friday, March 16, 2018 China FDA will take a new form; Celltrion's manufacturing issues might be worse than Teva hoped; Wuxi NextCODE and Google Cloud partner up.
FiercePharmaAsia—Takeda, Shanghai Pharma, WuXi NextCODE by Angus Liu Friday, January 26, 2018 Takeda-Zinfandel dropped an Alzheimer’s study; Shanghai Pharma will open an R&D site in the U.S.; NextCODE CEO talked about company plans.
FiercePharmaAsia—JSR, Orchid, Tessa and more by Angus Liu Thursday, December 21, 2017 Japan’s JSR bought Crown Biosciences, Aurobindo and Dr. Reddy’s responded to Orchid Pharma report, Tessa raised $80 million.
FiercePharmaAsia—WuXi NextCODE, Celltrion, Biocon by Angus Liu Friday, September 15, 2017 WuXi NextCODE has raised $240 million in series B, FDA slapped Celltrion with a long Form 483, Biocon's $275 million insulin plant opened shop.
FiercePharmaAsia—Takeda, WuXi NextCODE, Dr. Reddy’s by Angus Liu Friday, May 5, 2017 Takeda got FDA approval for Ariad-developed Alunbrig, WuXi NextCODE secured a $75 million Series B, and the FDA cited the third Dr. Reddy's plant this year.
